Tuberculosis remains one of the most consequential yet under-discussed threats to global longevity, and a sweeping new analysis spanning 33 years and 204 countries offers the most granular accounting yet of where progress is stalling — and why. For health-conscious adults accustomed to thinking of TB as a solved problem, the data deliver a sobering correction: the WHO's 2035 elimination targets are in serious jeopardy.
Drawing on the Global Burden of Disease Study 2023, researchers applied a rigorous multi-source modeling framework — integrating vital registration, surveillance data, verbal autopsies, and minimally invasive tissue sampling — to quantify TB mortality, incidence, prevalence, and disability-adjusted life-years (DALYs) from 1990 through 2023. A population attributable fraction methodology was used to disaggregate burden by HIV co-infection status and drug-resistance profile, including multidrug-resistant TB (MDR-TB). Additional risk factor analyses estimated the attributable fractions of alcohol use, tobacco smoking, and elevated fasting plasma glucose — three modifiable exposures with well-documented immunosuppressive or metabolic links to TB susceptibility and severity.
The findings arrive at a critical inflection point. While overall TB mortality has declined since 1990, the pace of reduction falls well short of the WHO End TB Strategy's benchmarks: a 95% drop in deaths and 90% drop in incidence by 2035 relative to 2015 baselines. MDR-TB and HIV-associated TB represent the most intractable sub-burdens, with treatment success rates and surveillance infrastructure lagging disproportionately in high-incidence regions. This is the first GBD cycle to use the DisMod-MR 2.1 platform for simultaneous age- and sex-stratified modeling of TB morbidity, improving internal consistency across estimates.
From a longevity science perspective, this analysis underscores how infectious disease burden interacts with chronic metabolic risk — elevated blood glucose and smoking accelerate TB progression in ways that blur the conventional line between communicable and non-communicable disease research. The study's limitations include data quality heterogeneity across low-income settings and reliance on modeled rather than directly observed estimates in many regions. Nevertheless, as global health funding faces contraction, this systematic baseline assessment is not merely incremental — it is the reference dataset against which any future TB elimination effort will be measured.